Regenerative Biology Research Laboratory, Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey.
Department of Biotechnology, Institute of Science, Yeditepe University, Istanbul, Turkey.
Adv Exp Med Biol. 2018;1079:37-53. doi: 10.1007/5584_2017_113.
The common prevalence of heart failure and limitations in its treatment are leading cause of attention and interest towards the induction of cardiac regeneration with novel approaches. Recent studies provide growing evidence regarding bona fide cardiac regeneration post genetic manipulations, administration of stimulatory factors and myocardial injuries in animal models and human studies. To this end, stem cells of different sources have been tested to treat heart failure for the development of cellular therapies. Endogenous and exogenous stem cells sources used in regenerative cardiology have provided a proof of concept and applicability of cellular therapies in myocardial improvement. Recent clinical studies, especially, based on the endogenous cardiac progenitor and stem cells highlighted the possibility to regenerate lost cardiomyocytes in the myocardium. This review discusses emerging concepts in cardiac stem cell therapy, their sources and route of administration, and plausibility of de novo cardiomyocyte formation.
心力衰竭的普遍流行和治疗的局限性是引起人们关注和兴趣的主要原因，促使人们寻求新方法来诱导心脏再生。最近的研究为基因操作、刺激因子的给药以及动物模型和人类研究中心肌损伤后真正的心脏再生提供了越来越多的证据。为此，已经测试了不同来源的干细胞来治疗心力衰竭，以开发细胞疗法。内源性和外源性干细胞来源在再生心脏病学中的应用为心肌改善的细胞疗法提供了概念和适用性的证据。特别是最近的临床研究，基于内源性心脏祖细胞和干细胞，强调了在心肌中再生丢失的心肌细胞的可能性。本综述讨论了心脏干细胞治疗的新出现的概念，包括它们的来源和给药途径，以及新生成心肌细胞的可能性。
